Company Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults.
Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults.
The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| Country | Israel |
| Founded | 2009 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Dror Ben-Asher |
Contact Details
Address: 21 Ha’arba’a Street Tel Aviv, 6473921 Israel | |
| Phone | 972 3 541 3131 |
| Website | redhillbio.com |
Stock Details
| Ticker Symbol | RDHL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001553846 |
| CUSIP Number | 757468103 |
| ISIN Number | US7574683014 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dror Ben-Asher | Co-Founder, Chairman and Chief Executive Officer |
| Razi Ingber | Chief Financial Officer |
| Adi Frish | Chief Corporate and Business Development Officer |
| Rick D. Scruggs | Chief Commercial Officer and Director |
| Gilead Raday MPhil, MSc | Chief Operating Officer |
| Alexandra Okmian | Senior Business Development and Investor Relations Manager |
| Dr. Reza Fathi Ph.D. | Senior Vice President of Research and Development |
| Guy Goldberg J.D. | Chief Business Officer |
| Patricia Anderson B.Sc. RAC | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2025 | EFFECT | Notice of Effectiveness |
| Jul 2, 2025 | 424B3 | Prospectus |
| Jul 1, 2025 | 6-K | Report of foreign issuer |
| Jun 25, 2025 | F-1 | Registration statement for certain foreign private issuers |
| Jun 25, 2025 | 6-K | Report of foreign issuer |
| May 27, 2025 | 6-K | Report of foreign issuer |
| May 19, 2025 | 6-K | Report of foreign issuer |
| May 13, 2025 | 6-K | Report of foreign issuer |
| May 5, 2025 | 6-K | Report of foreign issuer |
| May 2, 2025 | 6-K | Report of foreign issuer |